Recent regulations from Canada and the European Union surrounding data transparency in clinical trials have brought transparency standards and technology to the forefront for pharmaceutical companies. Last year, d-wise kicked off new research with pharmaceutical companies and contract research organizations on readiness for data transparency. Our findings are included in this whitepaper.
Objectives of our research included:
- Determine the state of transparency adoption processes
- Assess how sponsors plan on meeting regulatory deadlines, both currently and in future
- Identify pain points around data transparency
